
The Mounjaro Experience, Designed For Patients Like Julia1
Her T2D continues to progress she is ready for a change*
- Not to A1C goal on metformin
- Struggling to lose excess weight despite her efforts with diet and exercise

Actor portrayal of an adult woman with type 2 diabetes
*A patient you may see.
T2D=type 2 diabetes.
Get patients started on Mounjaro
Prescribe

Provide patients with:
a 2.5-mg prescription for 1 month*
a 5.0 mg prescription for 1 month or 3 months†
Activate

Help your eligible patients save on Mounjaro.
For eligible commercially insured patients with Mounjaro coverage. Governmental beneficiaries excluded, terms and conditions apply.
*One month is defined as 28 days and 4 pens.
†Three months is defined as 84 days and up to 12 pens.
The 2.5-mg dose is for treatment initiation and is not intended for glycemic control
Mounjaro Experience: Multiple doses for customizable glycemic control1‡
The 2.5 mg dose is for treatment initiation and is not intended for glycemic control.

Image depicting escalation of Mounjaro. Starting dose is 2.5 mg once weekly for 4 weeks. Continue to 5 mg once weekly for at least 4 weeks. If additional glycemic control is needed, dose can be increased to 7.5 mg once weekly for at least 4 weeks, then 10 mg once weekly for at least 4 weeks, then 12.5 mg once weekly for at least 4 weeks, and then 15 mg once weekly as a maximum dose.
‡Consider patient history and monitor for tolerability and side effects.
Start Mounjaro1:
- Initiate with the 2.5-mg dose once weekly
- After 4 weeks on the 2.5-mg dose, increase to the 5-mg dose once weekly
If additional glycemic control is needed, you can continue to increase the dose by 2.5-mg increments after at least 4 weeks on the current dose. The maximum dose is 15 mg once weekly.
The 2.5 mg dose is for treatment initiation and is not intended for glycemic control.
Writing Mounjaro1

The amount to be dispensed may be written as "4 pens" for a 28-day supply or "12 pens" for an 84-day supply.
Image depicting how to write the prescription for different doses of Mounjaro. All doses are injected subcutaneously once weekly and dispensed as 1 box or 4 pens for a 28-day supply. 2.5-mg dose NDC: 0002-1506-80; 5-mg dose NDC: 0002-1495-80; 7.5-mg dose NDC: 0002-1484-80; 10-mg dose NDC: 0002-1471-80; 12.5-mg dose NDC: 0002-1460-80; 15-mg dose NDC: 0002-1457-80.
More doses to help achieve individual glycemic goals1

Image showing all 6 Mounjaro pen doses available: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
The 2.5 mg dose is for treatment initiation and is not intended for glycemic control.
- A single-use, once-weekly, auto-injection pen with a hidden needle
- Available in 6 doses: a 2.5-mg starting dose and 5-mg, 7.5-mg, 10-mg, 12.5-mg, and 15-mg doses
Add Mounjaro to EHR Order Sets for Type 2 Diabetes in Adults
Help patients get from initiation to a therapeutic dose of Mounjaro
Storing and dispensing the Mounjaro pen1
Store Mounjaro in a refrigerator at 36°F to 46°F (2°C to 8°C)
- If needed, each single-dose pen can be stored unrefrigerated at temperatures not to exceed 86°F (30°C) for up to 21 days
- Do not freeze Mounjaro. Do not use Mounjaro if frozen
- Store Mounjaro in the original carton to protect from light
Getting patients started1
Here is some information to help patients get started on Mounjaro:
- Remind patients that Mounjaro is taken once weekly and comes in a single-dose pen with a no-see needle1
- Advise the patient to read the Instructions for Use2
- Allow the patient to practice the injection using the demonstration device
- Consider having the patient administer the first dose in the office
-
Set expectations that Mounjaro may cause some side effects:
- Discuss the Boxed Warning and other warnings/precautions as appropriate for your patient
-
Patients may experience nausea, diarrhea, or vomiting.3 Patients may find it helpful to4-6:
- Eat smaller meals–try splitting your 3 daily meals into 4 or more smaller ones
- Stop eating when you feel full
- Avoid fat or fatty foods
- Try eating bland foods like toast, crackers, or rice
- Mounjaro delays stomach emptying, so it may make birth control pills less effective. Recommend to female patients using oral hormonal birth control to switch to a non-oral birth control method or add a barrier method of birth control for 4 weeks after initiation and for 4 weeks after each dose escalation3
- If a dose is missed, instruct patients to administer as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose, and administer the next dose on the regularly scheduled day
Side effects may vary and should be evaluated by the healthcare provider for appropriate management.
Select Important Safety Information
Risk of Thyroid C-cell Tumors: Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
SC=subcutaneous; T2D=type 2 diabetes.
References:
- Mounjaro. Instructions for Use. Lilly USA, LLC.
- Mounjaro. Medication Guide. Lilly USA, LLC.
- Mounjaro. Prescribing Information. Lilly USA, LLC.
- Maceira E, Lesar TS, Smith HS. Medication related nausea and vomiting in palliative medicine. Ann Palliat Med. 2012;1(2):161-176.
- Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diabetes Educ. 2010;36(Suppl 3):44S-72S.
- Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes. 2013;31(4):148-157.